Relating to authorizing the Department of Health to promulgate a legislative rule relating to laboratories of the Medical Cannabis Program
Summary
HB2247 is a rule-authorization bill that approves a legislative rule for the West Virginia Department of Health concerning laboratories used in the Medical Cannabis Program. The bill does not itself create a new cannabis laboratory program or rewrite the underlying medical cannabis statutes; instead, it gives legislative approval to a previously filed rule, identified as 64 CSR 111, governing how those laboratories operate.
In practical terms, the bill allows the Department of Health to move forward with regulatory standards for testing and oversight of medical cannabis laboratories. Those standards may address issues such as laboratory qualifications, testing procedures, quality control, and compliance requirements for entities involved in the medical cannabis supply chain. The bill’s effect is therefore administrative and regulatory, rather than a broad policy change to the medical cannabis law itself.
Impact
HB2247 amends West Virginia Code §64-5-1 to authorize a specific legislative rule under the Department of Health’s authority in §16A-3-1. Its legal effect is to validate the rule for laboratories in the Medical Cannabis Program, making the rule enforceable and part of the state’s regulatory framework. The bill primarily affects the Department of Health, medical cannabis laboratories, and indirectly medical cannabis growers, processors, dispensaries, and patients who rely on testing and product safety oversight.
Sentiment
No committee transcript or vote record is provided, so there is no direct evidence of debate or opposition in the available materials. Based on the bill’s narrow scope and procedural nature, the measure appears to be a routine administrative authorization rather than a controversial policy proposal. The available context suggests a neutral or procedural posture toward the bill.
Contention
The bill text itself does not identify any disputed provisions, and there are no recorded committee comments or votes in the provided context. If any contention exists, it would likely center on the underlying medical cannabis regulatory framework—such as testing standards, laboratory accreditation, compliance burdens, or the Department of Health’s rulemaking authority—but those concerns are not documented in the materials supplied.